蒙卢南班特通过一个中心机制抑制食欲
Priya Mullassaril1, Lucy Brodkin, Jesse Brodkin
1Behavioral Instruments, Hillsborough, New Jersey, USA.
Behavioural pharmacology
|February 19, 2025
概括
肥胖药物蒙卢南班特通过影响中央大麻素受体1 (CB1) 受体而不是外围受体来抑制食欲. 这表明潜在的精神病风险与较旧的CB1抗剂相似.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学 是一个学科.
- 肥胖问题研究研究
背景情况:
- 大麻素受体1 (CB1) 抗剂蒙卢南邦特 (monlunabant) 是通过向外围受体来治疗肥胖而开发的.
- 之前的CB1抗剂,如里莫纳班特,显示出有效性,但带有不良精神影响的风险.
- 单南丁的确切作用机制,特别是中央与外围CB1受体的参与,仍然不清楚.
研究的目的:
- 通过中枢神经系统的CB1受体,研究单南丁是否会通过中枢神经系统的CB1受体发挥抑制食欲的作用.
- 为了比较monlunabant和rimonabant在活体中调节CB1受体活性中的功效.
- 评估隆班特对中央CB1受体抗的潜力及其对不良影响的含义.
主要方法:
- 用成年雄性小鼠来评估隆邦特和里莫纳邦特对食欲和低温的影响.
- 用CB1激素激剂诱导的低温症作为评估受体对抗性的模型.
- 胃口抑制是在缺乏食物的小鼠中测量的,这些小鼠获得偏好的食物的机会有限.
主要成果:
- 莫隆纳班特和里莫纳班特都降低了小鼠的食欲,并对抗了CB 1激动剂诱导的低温症.
- 在两种观察到的效果中,蒙卢南邦的效果始终低于里莫纳班.
- 观察到Monlunabant的剂量可能涉及中央CB1受体对抗作用,而不是外围和,观察到食欲抑制.
结论:
- 蒙卢南本的食欲抑制作用主要通过对中央CB1受体的对抗作用进行介导.
- 这些发现表明,隆可能与里莫纳班特具有类似的不良精神病影响风险.
- 针对肥胖症开发的第二代CB1抗剂需要仔细评估与中枢神经系统相关的副作用.
相关概念视频
01:30Regulation of Food Intake
179
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
179
01:23Antidepressant Drugs: MAOIs and Other Agents
181
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
181
01:25Adrenergic Agonists: Indirect-Acting Agents
1.5K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.5K
01:24Glucagon-like Receptor Agonists
291
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
291
01:40Hormonal Regulation
43.1K
Hormones regulate a significant portion of digestion through activation of the neuroendocrine system. The neuroendocrine system of digestion contains many different hormones all with multiple functions that are both, directly and indirectly, involved in digestion.
43.1K
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
204
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
204